Abstract
Background/Objectives: To date, nearly 300 lentiviral-based gene therapy clinical trials have been conducted, with eight therapies receiving regulatory approval for commercialization. These advances, along with the increased number of advanced-phase clinical trials, have prompted contract development and manufacturing organizations (CDMOs) to develop innovative strategies to address the growing demand for large-scale batches of lentiviral vectors (LVVs). Consequently, manufacturers have focused on optimizing processes under good manufacturing practices (GMPs) to improve cost-efficiency, increase process robustness, and ensure regulatory compliance. Nowadays, the LVV production process mainly relies on the transient transfection of four plasmids encoding for the lentiviral helper genes and the transgene. While this method is efficient at small scales and has also proven to be scalable, the industry is exploring alternative processes due to the high cost of GMP reagents, and the batch-to-batch variability predominantly attributed to the transfection step. Methods: Here, we report the development and implementation of a reliable and clinical-grade envisioned platform based on the generation of stable producer cell lines (SCLs) from an initial well-characterized lentiviral packaging cell line (PCL). Results: This platform enables the production of VSV-G-pseudotyped LVVs through a fully transfection-free manufacturing process. Our data demonstrate that the developed platform will facilitate successful technological transfer to large-scale LVV production for clinical application. Conclusions: With this simple and robust stable cell line generation strategy, we address key concerns associated with the costs and reproducibility of current manufacturing processes.
Share and Cite
MDPI and ACS Style
Arrasate, A.; Bravo, I.; Lopez-Robles, C.; Arbelaiz-Sarasola, A.; Ugalde, M.; Meijueiro, M.L.; Zuazo, M.; Valero, A.; Banos-Mateos, S.; Ramirez, J.C.;
et al. Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing of Clinical-Grade Lentiviral Vectors. Biomedicines 2024, 12, 2265.
https://doi.org/10.3390/biomedicines12102265
AMA Style
Arrasate A, Bravo I, Lopez-Robles C, Arbelaiz-Sarasola A, Ugalde M, Meijueiro ML, Zuazo M, Valero A, Banos-Mateos S, Ramirez JC,
et al. Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing of Clinical-Grade Lentiviral Vectors. Biomedicines. 2024; 12(10):2265.
https://doi.org/10.3390/biomedicines12102265
Chicago/Turabian Style
Arrasate, Ane, Igone Bravo, Carlos Lopez-Robles, Ane Arbelaiz-Sarasola, Maddi Ugalde, Martha Lucia Meijueiro, Miren Zuazo, Ana Valero, Soledad Banos-Mateos, Juan Carlos Ramirez,
and et al. 2024. "Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing of Clinical-Grade Lentiviral Vectors" Biomedicines 12, no. 10: 2265.
https://doi.org/10.3390/biomedicines12102265
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.